Under Consideration | GenomeWeb

Under Consideration

Vertex Pharmaceuticals' cystic fibrosis drug, Orkambi, goes in front of a US Food and Drug Administration advisory committee this week, the Wall Street Journal reports.

The drug is being targeted to patients with cystic fibrosis patients who have a certain genetic mutation. Vertex also makes the cystic fibrosis drug Kalydeco.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.